The UL144 gene product of human cytomegalovirus activates NFκB via a TRAF6-dependent mechanism

Emma Poole1, Christine A King1, John H Sinclair1 and Antonio Alcami1,2,*

1Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK and 2Centro Nacional de Biotecnología (CSIC), Campus de Cantoblanco, Madrid, Spain

Molecular mimicry of cytokines and cytokine receptors is a strategy used by poxviruses and herpesviruses to modulate host immunity. The human cytomegalovirus (HCMV) UL144 gene, situated in the UL/b region of the viral genome, has amino-acid sequence similarity to members of the tumour necrosis factor receptor superfamily. We report that UL144 is a potent activator of NFκB-induced transcription in a TRAF6-dependent manner. This NFκB activation enhances expression of the chemokine CCL22 through the NFκB responsive elements found in its promoter. In contrast to the clinical HCMV isolates, extensively passaged laboratory strains lack the UL/b region and hence do not encode UL144. Consistent with this, infection with viruses that carry UL/b causes NFκB activation and CCL22 expression, a phenotype that is not observed after infections with strains lacking the UL/b region. Moreover, knockdown of UL144, TRAF6 or NFκB by specific siRNA in infections with UL144-encoding HCMV prevents the activation of CCL22 expression normally observed after infection with UL/b positive HCMV. Upregulation of CCL22, which attracts Th2 and regulatory T cells, may help HCMV evade immune surveillance. The EMBO Journal (2006) 25, 4390–4399. doi:10.1038/sj.emboj.7601287; Published online 24 August 2006

Subject Categories: immunology; microbiology & pathogens
Keywords: chemokine; human cytomegalovirus; immune evasion; NFκB; TNF receptor superfamily

Introduction
Human cytomegalovirus (HCMV) is a member of the beta-herpesvirus family. It is species-specific and can cause severe disease in neonates and in immunosuppressed individuals such as allograft transplant recipients and patients with AIDS (Pass, 2001), although the exact disease mechanisms are unclear. The HCMV genome comprises 236 kb of dsDNA, one of the largest human virus, and many of its genes are nonessential for replication in fibroblasts (Dunn et al, 2003). The long 15 kb unique region UL/b contains at least 19 open reading frames (ORFs) that are found in HCMV clinical isolates but have been lost in extensively passaged laboratory strains and are dispensable for growth in vitro (Cha et al, 1996). The retention of these ORFs in HCMV clinical isolates together with recent evidence that clinical isolates, but not the attenuated laboratory strain AD169, can replicate in SCID mice into which human tissues were implanted suggest that the UL/b region is required for viral infection in vivo (Wang et al, 2005). Consistent with this, some of the UL/b region genes may be implicated in immune evasion, such as the chemokine homologues UL146 and UL147 (Hengel et al, 1998; Mocarski, 2002). The UL144 ORF is encoded in the UL/b region and a candidate for a pathogenesis marker because of its sequence similarity to the herpes simplex virus entry mediator (HveA or HVEM) (Benedict et al, 1999) and other members of the tumour necrosis factor receptor superfamily (TNFRSF) (Locksley et al, 2001; Ware, 2003), which are critical for defence against viral pathogens such as HCMV (Quinnan et al, 1984).

Avoidance of the host immune system by viruses is commonplace (Alcami and Koszinowski, 2000; Tortorella et al, 2000). Some viruses, such as Adenovirus, HCMV and Epstein–Barr virus (EBV), prevent cell surface expression or colocalization of specific receptors. Mimicry of cytokines and cytokine receptors is a mechanism of immune evasion identified in large DNA viruses (poxviruses and herpesviruses) (McFadden and Murphy, 2000; Alcami, 2003). Poxviruses encode secreted decoy receptors for cytokines and chemokines that intercept immune communications. Poxvirus TNFR homologues have amino-acid sequence similarity to the extracellular TNF binding domain of the cellular counterparts but lack the transmembrane and cytoplasmic domains, and hence they are secreted and neutralize TNF activity. A homologue of CD30, another TNFRSF member, has also been identified in poxviruses. UL144 encoded by HCMV is the only TNFRSF member identified in herpesviruses. In contrast to the poxvirus secreted TNFR homologues, UL144 has a transmembrane domain and a short cytoplasmic tail, and it is a membrane-anchored glycoprotein retained intracellularly (Benedict et al, 1999). UL144 may act as a decoy receptor but no interaction with members of the TNF superfamily (TNFSF) has been identified so far. Recently, the ectodomain of UL144 has been shown to interact with B and T lymphocyte attenuator (BTLA), belonging to the Ig superfamily, and to inhibit T cell proliferation in vitro (Cheung et al, 2005).

Viruses also modulate the immune response by interfering with transcription and signalling pathways of the host cell. The V protein of SV5, for example, causes the degradation of signal transducers and activators of transcription 1 and prevents dsRNA signalling to the interferon (IFN) promoter in an IFN regulatory factor 3 (IRF-3) dependent manner (Poole et al, 2002). The poxviral protein N1L blocks IRF-3 signalling via the toll-like receptor (TLR) pathway (DiPerna et al, 2004).
Viruses also target the NFκB pathway, which is shared by several proinflammatory cytokines, such as TNF and interleukin 1 (IL-1), and TLRs (Li and Verma, 2002; Dempsey et al., 2003; Bonizzi and Karin, 2004). TNFR-activated factor 6 (TRAF6) is a mediator of NFκB activation and signals through protein kinase cascades via activation of the TAK1 complex. TAK1 phosphorylates and activates the IκB kinase complex, which then phosphorylates the NFκB inhibitor IκB, targeting it for ubiquitination and subsequent proteasome-mediated degradation. NFκB is then freed to enter the nucleus where it can act as a transcription factor. Viruses may prevent or enhance NFκB activation. For example, poxvirus proteins N1L and K1L interfere with the IκB kinase complex (DiPerna et al., 2004; Shisler and Jin, 2004) and prevent NFκB activation whereas latent membrane protein 1 (LMP1) protein of EBV activates the TRAF-mediated NFκB pathway (Schultheiss et al., 2001; Nakayama et al., 2004).

Here, we report that the UL144 protein of HCMV upregulates NFκB-dependent transcription through a mechanism involving TRAF6. We also show that this UL144-induced NFκB activation is concomitant with an increased expression of CCL22 (macrophage derived chemokine, MDC), a chemokine implicated in the attraction of Th2 cells, which may reduce host Th1 immune responses and be advantageous for HCMV in vivo.

Results

UL144 does not bind to members of the human TNFSF

Amino-acid sequence similarity of UL144 to HVEM and other TNFRSF members has been reported but no binding of the recombinant UL144 ectodomain fused to the Fc portion of IgG1 to TNF-related ligands was detected by ELISA (Benedict et al., 1999; Lurain et al., 1999). We investigated whether UL144 interacts with members of the TNFSF by surface plasmon resonance (SPR, Biacore X). The extracellular domain of UL144 from the HCMV low-passage strain Toledo, lacking the transmembrane domain and short cytoplasmic tail, was expressed in the baculovirus system and purified by affinity chromatography. We were unable to detect specific binding of 100 nM human recombinant TNFSF 1, 2, 4, 5, 6, 8, 9, 10, 11, 12, 13, 13b, 14, 15 and 18 to purified UL144 by SPR (not shown). As a control, we observed binding of the ectromelia virus TNFR CrmD to TNF (not shown).

UL144 in isolation and viruses containing UL144 are capable of inducing NFκB

The possibility that UL144 may modulate intracellular signalling pathways involved in antiviral responses was investigated (Figure 1). UL144 from HCMV Toledo was expressed in human U373 cells, a cell line fully permissive for HCMV productive infection, and tested for its ability to repress or activate these signalling pathways. Figure 1B shows that UL144 has no effect on basal or activated levels of IFN-γ stimulated gene expression to the ISRE reporter. UL144 also had no effect on the IFN-β promoter, which contains an NFκB binding site and neither did it have any effect on activation of this promoter by dsRNA (Figure 1A) or the dsRNA-induced activation of IRF3 (Figure 1C). However, UL144 may activate NFκB in other promoters as the dsRNA responsive promoter requires concomitant activation of other transcription factors, such as IRF-3 (Figure 1A). Interestingly, we found that UL144

Figure 1 The UL144 protein of HCMV activates NFκB but not IRF3, IFN induction or response. Human U373 cells (A–D) were transfected with a luciferase reporter for IFN-β [pIFNβ(-125)luc] (A), type I IFN responsiveness [p(9–27ISRE)αtk(A–39)luc] (B), IRF-3 activation p(lexOP)2TCLuc and Lex-IRF3 (C) or NFκB activation p(PRDI)αtk(Δ−39)luc] (D) plus a reporter for β-galactosidase activity (pJATlac). Cells were also transfected with either a mammalian vector driving the overexpression of UL144 protein (pCDNA3UL144) or the control empty vector (pCDNA3). Forty-eight h post-transfection, cells were either mock-treated (−) or treated (+) with poly(I)-poly(C) (dsRNA) for 10 h (A, C), IFN zi2a for 5 h (B) or TNF for 5 h (D). Luciferase activity was determined from cellular extracts and expression values calculated as the fold increase with respect to the level induced in cells transfected with pCDNA3 and reporter plasmid in the absence of stimulation. Experiments were repeated at least twice and mean±s.d. from representative experiments (A–C duplicates and D, triplicate samples) is shown.

© 2006 European Molecular Biology Organization The EMBO Journal VOL 25 | NO 18 | 2006 4391
activated NFκB-dependent activity of the PRDII promoter in the absence of inducers such as TNF. Additionally, UL144 and TNF had a cumulative effect indicating that the mechanism that UL144 uses to stimulate NFκB may be separate from the TNF signalling pathway (Figure 1D). Specific activation of NFκB was also observed in similar UL144 transfection with the PRDII promoter in experiments performed in Vero and 293 T cells (not shown).

To determine the ability of UL144 to activate NFκB in the context of HCMV infection, viruses containing UL144 were compared with UL144 negative laboratory strains for their ability to activate an NFκB responsive promoter PRDII in human U373 cells that support HCMV replication (Figure 2). At 48 h postinfection, when levels of infection were comparable for both UL/b' positive and negative HCMVs (Figure 2A) and the time at which UL144 is maximally expressed (Benedict et al., 1999), HCMV TB40E caused a potent activation of NFκB but the UL144-deficient HCMV Towne did not (Figure 2B). Consistent with the results from UL144 expression alone, there was no difference in activation of the IFN-stimulated ISRE reporter (not shown). Furthermore, the inability of HCMV Towne, which does not contain the UL/b' region, to activate the PRDII NFκB responsive promoter was complemented by transfection of pCDNA3UL144 (Figure 2C).

Consistent with the activation of NFκB by UL144, we observed relocalization of the p65 subunit of NFκB, both endogenous and transfected GFP p65, in cells transfected with pCDNA3UL144 and not after transfection with control pCDNA3 (not shown). As predicted from the reporter assay, transfection of pCDNA3UL144 did not cause nuclear translocation of IRF3 (not shown).

**The mechanism of NFκB activation by UL144 is TRAF6-dependent**

NFκB activation often involves one or more of the TNF signalling pathway components, such as TRAF2 and TRAF6. These proteins complex with cell surface proteins, such as TNFRs as well as those involved in release of NFκB from the inhibitory protein IκB (Li and Verma, 2002; Dempsey et al., 2003; Bonizzi and Karin, 2004). Initial immunofluorescence experiments in U373 cells showed no relocalization of TRAF2 following infection with HCMV strains containing or lacking UL144, or after UL144 transfection (not shown). Interestingly, infection with HCMV TB40E containing the UL144 gene caused TRAF6 (normally diffused and difficult to detect in the cytoplasm; Figure 3A), to accumulate in the perinuclear region (Figure 3B), whereas infection with the high passage HCMV AD169, lacking UL144, did not (Figure 3A). Perinuclear localization of TRAF6 has been reported previously and is believed to occur following activation, for example, CD40 ligation (Gentry et al., 2004).

We tested the possibility that UL144 and TRAF6 physically interacted in vivo by a number of techniques (Figure 4). Firstly, indirect immunofluorescence clearly showed that UL144 and TRAF6 co-localized in transfected cells (Figure 4A, right-hand panels). This was verified by using co-localization detection software (areas of co-localization shown in white in Figure 4B, left hand panel). We also analysed this co-localization by FRET analysis (Figure 4C). FRET occurs when two juxtaposed molecules reside 6 nm or less apart, and this analysis shows that red photobleaching of endogenous TRAF6 staining (Figure 4B, right-hand panel showing an absence of red staining) caused an increase in intensity of transfected UL144 green fluorescence (Figure 4C, left and right panels). Statistical analysis was consistent with

Figure 2  NFκB activation with HCMV and UL144. Human U373 cells were infected with HCMV Towne (A) or TB40E (B) at an MOI of 1 PFU/cell. IE gene expression was quantified by FACS analysis of IE72-GFP (A) or with specific antibody to IE-72 (B). In (A), grey histograms represent uninfected controls and black histograms represent IE-GFP expression. In (B), grey histograms represent isotype stained controls and black histograms represent IE-72 positive cells. Numbers represent percentage of the population expressing IE genes. (C, D) U373 cells were transfected with the reporter construct for NFκB activity [p[PRDII]-tkluc(-39)]luciferase and pIATAC (C, D) and pCDNA3 or pCDNA3UL144 (D) for 24 h before being mock-infected or infected with the indicated virus (moi 5 PFU/cell). Luciferase activity was determined 48-h postinfection from cellular extracts and the expression values calculated relative to the basal levels of luciferase activity in uninfected cells. Experiments were repeated at least twice and mean ± s.d. from representative experiments (C and D, triplicate samples) is shown.

Figure 3  A UL144-containing HCMV, but not a virus lacking UL144, causes perinuclear accumulation of TRAF6. Human U373 cells were infected with HCMV AD169 (A) or TB40E (B). Infection was detected with FITC-conjugated monoclonal antibody specific for the HCMV immediate early protein IE72 (green, E13 antibody) and TRAF6 with rabbit polyclonal antibody followed by anti-rabbit TRITC (red).
molecules of UL144 and TRAF6 being in very close proximity (Figure 4D). Taken together these results indicated that UL144 interacts with TRAF6 in the perinuclear region of the cell. Moreover, UL144 was able to complex with TRAF6 as determined by immunoprecipitation followed by Western blot analysis in UL144-transfected U373 cells (Figure 5) and 293 T cells (not shown). Note the specific co-precipitation of TRAF6 with antibodies to T7-taged UL144 and not control IgG, from cell extracts containing comparable amounts of TRAF6.

To test the functional significance of the interaction between TRAF6 and UL144, TRAF6 as well as TRAF2 expression were knocked down in U373 cells by siRNAs (Figure 6A). The amount of TRAF6 and TRAF2 proteins were completely abrogated after 2 days, whereas treatment with control siRNAs did not reduce either TRAF6 or TRAF2 levels. Figure 6B shows that UL144 was unable to activate an NFκB-dependent promoter (PRDII) after TRAF6 knockdown, but could activate it after transfection of cells with control or TRAF2 siRNA. These findings indicated that the mechanism by which UL144 activates the NFκB promoter is TRAF6-dependent, but not TRAF2-dependent. Furthermore, we also found that cells infected with HCMV TB40E expressing UL144 were unable to activate the NFκB responsive reporter in the presence of TRAF6 siRNA (Figure 6C), confirming that TRAF6 is involved in UL144-mediated activation of NFκB in the context of virus infection.

UL144-mediated activation of NFκB causes upregulation of the chemokine CCL22

Since the UL144 gene is contained within a region of the HCMV genome that is dispensable for virus replication in tissue culture, UL144 may play a role in the regulation of host genes involved in immune evasion. To test this, cytokine protein array analysis that included 120 cytokines and cytokine receptors was carried out on media from human foreskin fibroblast (HFF) cells infected with HCMV TB40E, containing UL144, or Towne, which lacks UL144. We found that several cytokines were affected differently by HCMV TB40E and Towne. Cytokines downregulated by HCMV TB40E included IGF BP-1 (insulin-like growth factor binding protein 1) (five-fold decrease); IL-4 (four-fold decrease); CXCL7 (neutrophil activating peptide 2, NAP2) (four-fold decrease); CCL5 (regulated on activation, normal T-cell expressed and secreted, RANTES) (three-fold decrease) and LTα (lymphotoxin α) (three-fold decrease). Cytokines upregulated included GDNF (glial cell line-derived neurotrophic factor) (three-fold increase); IL-1β (three-fold increase); IL-2 (five-fold increase); LIGHT (lymphotoxin-inducible expression competes with herpes simplex virus glycoprotein D for HVEM T-lymphocyte receptor) (four-fold increase) and CCL22 (seven-fold increase).

Since the chemokine CCL22 was the cytokine substantially upregulated, we explored this further. Figure 7 shows that supernatants from human U373 cells infected with UL144-expressing HCMV TB40E and Toledo upregulated CCL22 expression as determined by ELISA. Moreover, this increase in CCL22 expression was recapitulated in UL144 transfected cells. No such increase in CCL22 expression was observed in
Interestingly, HCMV Towne was able to induce CCL22 when cells were transfected with pCDNA3UL144 (Figure 7). Consistent with our observation that UL144 may mediate the activation of specific NFκB-dependent promoters, the CCL22 promoter contains two NFκB binding sites (Nakayama et al., 2004). This chemokine is chemoattractant for Th2 and T regulatory cells, and therefore UL144 may evade the immune system by enhancing the Th2 response and subverting the Th1 response.

UL144 expressed from HCMV induces CCL22 upregulation through a TRAF6- and NFκB-dependent mechanism

The results reported above suggested that the upregulation of the chemokine CCL22 in cells infected with UL144-containing HCMV was mediated by UL144 expression; transfection of UL144 was sufficient to induce the activation of NFκB-dependent promoters through TRAF6 and upregulation of CCL22 expression, and this effect was not observed in cells infected with laboratory strains of HCMV lacking UL144. However, the UL/b0 region present in the HCMV strains tested here encode up to 18 other ORFs and these other proteins may also activate NFκB. The rescue of CCL22 expression in cells infected with laboratory strains after UL144 transfection suggested that UL144 alone was responsible for CCL22 upregulation. We confirmed this by blocking UL144 expression in HCMV TB40E-infected U373 cells with siRNAs. Since UL144 is highly variable among HCMV clinical isolates (Lurain et al., 1999), the sequences of the UL144 siRNAs were designed to specifically inhibit the expression of UL144 encoded by either TB40E or Toledo. The effectiveness and specificity of these siRNAs to inhibit UL144 expression was monitored (Figure 8A). Densitometric analysis showed 85% inhibition of UL144 expression with TB40E-specific siRNA and 77% inhibition with Toledo-specific siRNA.
Figure 8B shows as expected that CCL22 upregulation was only observed in infections with HCMV TB40E and Toledo, and not in uninfected cells or cells infected with Towne. UL144-specific siRNAs specifically inhibited CCL22 upregulation by HCMV TB40E or Toledo demonstrating that UL144 is the only protein encoded by these viruses causing this effect. Moreover, the inhibition of CCL22 expression in HCMV TB40E infections by siRNA specific for UL144 from TB40E but not by siRNA specific for UL144 from the Toledo, and vice versa, further demonstrated the specificity of the siRNA inhibitory effect. The inhibition of CCL22 expression by TRAF6 or NFκB siRNAs confirmed that these cellular factors are also required for the UL144-induced CCL22 upregulation observed in infections with UL144-expressing HCMV (Figure 8B). Similarly, the CCL22 upregulation observed after infection of human fibroblast HFF cells infected with HCMV TB40E and Toledo was also inhibited by siRNA specific for UL144, TRAF6 and NFκB (not shown).

The LMP1 protein encoded by EBV also activates NFκB and induces CCL22 expression, and the NFκB sites in the CCL22 promoter are important for this upregulation of CCL22 transcription by LMP1 (Nakayama et al., 2004). However, UL144 may not work through the same mechanism. To address the dependence of the CCL22 promoter on NFκB sites in the regulation by UL144, a series of luciferase constructs driven by the CCL22 promoter and mutants thereof were tested (Nakayama et al., 2004). Figure 9A shows that removal of the NFκB sites specifically prevented UL144-mediated induction of the CCL22 promoter whereas deletion of the AP1 site had no effect.

The activation of the alternative pathway of NFκB activation by UL144 was addressed. Figure 9B shows that transfection of U373 cells with pCDNA3UL144 caused the specific degradation of NFκB2/p100 and the generation of the truncated p52 product, an event characteristic of the alternative pathway of NFκB activation (Bonizzi and Karin, 2004).

Discussion

The large coding capacity of the genome of herpesviruses and poxviruses enables the acquisition of a variety of genes that modulate the host immune response. Some of these immune evasion genes mimic cytokine and cytokine receptors involved in immune regulation (McFadden and Murphy, 2000; Alcami, 2003). Secreted decoy receptors for cytokines have been identified almost exclusively in poxviruses and only three examples have been described in herpesviruses (Alcami, 2003): a granulocyte–macrophage colony stimulating factor binding protein encoded by EBV and three chemokine binding proteins encoded by murine gammaherpesvirus 68, alphasporoviruses and HCMV (Alcami, 2003; Bryant et al., 2003; Wang et al., 2004). These herpesvirus decoy receptors lack amino-acid sequence similarity to their cellular counterparts. By contrast, the UL144 protein encoded by HCMV is a homologue of HVEM and other TNFRSF members, and is anchored into cell membranes.
The presence in UL144 of cysteine-rich domains (CRDs) characteristic of TNFRSF members suggests that UL144 may interact with TNFSF members, but previous studies have failed to identify a ligand partner for UL144 by ELISA (Benedict et al., 1999). Here, we have extended those studies to other TNFSF members and used a different and highly sensitive methodology (SPR) to screen for potential ligands, but we have failed to detect any specific interaction of TNFSF members with UL144. The fact the UL144 lacks CRD3, which has been implicated in binding of TNFR to LTα, led to the suggestion that UL144 may not possess a ligand binding domain (Benedict et al., 1999). Recently, UL144 has been shown to interact with the Ig superfamily member BTLA, mimicking the interaction of HVEM with BTLA, and to inhibit T-cell proliferation in vitro (Cheung et al., 2005). HVEM also interacts with LIGHT but no interaction of UL144 with LIGHT has been detected (this report) (Benedict et al., 1999).

In contrast to the decoy receptor function of the other viral cytokine receptors, the recent demonstration that UL144 interacts with BTLA suggests that UL144 mimics the inhibitory co-signalling function of HVEM and may modulate T-cell responses (Cheung et al., 2005). Here, we report a different and complementary function of UL144, which takes place within the infected cell: the activation of NFκB signalling. This activation was demonstrated by expression of UL144 in cells and, most important, during the infection with UL144-containing HCMV. Altogether, several lines of evidence suggest that UL144 is the only gene responsible for the observed activation of NFκB in HCMV infections: (i) this NFκB activation does not occur in infections with HCMV laboratory strains lacking UL144; (ii) expression of UL144 in cells infected with UL144-deficient viruses induces NFκB activation; and (iii) the HCMV strain-specific inhibition of UL144 expression with siRNA prevented CCL22 upregulation, which is dependent on NFκB activation. The induction of the alternative pathway of NFκB activation by UL144, causing the degradation of NFκB2/p100 into p52 (Bonizzi and Karin, 2004), was also demonstrated in transfected cells.

The mechanism by which UL144 activates NFκB is TRAF6-dependent and UL144 appears to achieve this by sequestering TRAF6 in the perinuclear region. Our results show that TRAF6 and UL144 are part of a larger complex and that they are in close proximity, as indicated by co-precipitation and co-localization analyses. However, we do not know whether UL144 and TRAF6 interact directly and the possibility that this interaction is mediated by other proteins has yet to be determined. The short cytoplasmic tail of UL144 has a YXXZ motif (Z is a hydrophobic amino acid) that is important in sorting of transmembrane proteins, and mutations of the tyrosine residue causes a higher expression of UL144 at the cell surface (Benedict et al., 1999). However, the cytoplasmic tail of UL144 lacks the motifs implicated in interactions with TRAFs. The inhibition of UL144-induced CCL22 upregulation by siRNA specific for TRAF6 or NFκB establishes the requirement of these cellular factors for this function of UL144 within HCMV-infected cells.

The high amino-acid sequence variability in the UL144 protein encoded by HCMV clinical isolates is relevant considering the high conservation of other proteins, and has classified the isolates in three major groups (Lurain et al., 1999). Interestingly, all the amino-acid variability is found in the signal peptide and ectodomain of UL144, with 16–21% of amino-acid substitutions, mostly nonconservative, between isolates belonging to group 1 and groups 2/3. The finding that the transmembrane and cytoplasmic domains of UL144 are identical among 45 clinical isolates, with the exception of a R161K substitution in four isolates, is striking and strongly suggests that these domains are important for the correct function of UL144. The sequence of UL144 from the two UL144-containing viruses tested in our studies belong to the group 1 (Toledo) and group 3 (TB40E) and are highly divergent in their ectodomain (Dolan et al., 2004), with a single L151F substitution in the transmembrane domain of the UL144 from TB40E. Our finding that both these UL144 variants are able to induce NFκB activation, transduce signalling through TRAF6 and upregulate CCL22 production, either
after UL144 transfection or upon virus infection, would be consistent with the conserved regions being involved in this function of UL144.

Viral proteins may evade cell signalling immune system pathways (Goodbourn et al., 2000; Andrejeva et al., 2002; Poole et al., 2002; Iqbal et al., 2004; Nakayama et al., 2004). Interestingly, like HCMV UL144, the LMP1 protein of EBV also upregulates NFκB but through a different mechanism. LMP1 has six transmembrane segments and is unrelated to members of the TNFRSF, but its long cytoplasmic domain resembles that of TNFRSF members and acts as a docking site for recruiting and activating signalling proteins including TRAF6 (Eliopoulos and Young, 2001; Schultheiss et al., 2001; Li and Chang, 2003). The HVEM homologue UL144 lacks a long cytoplasmic tail, but UL144 appears to act like LMP1 as a constitutive activator of NFκB and also engages TRAF6 (Schultheiss et al., 2001). Thus, different human herpesviruses, EBV and HCMV, have evolved unrelated proteins to subvert the NFκB pathway for their benefit.

The transcription factor NFκB is critical for mounting both innate and adaptive immune responses to infection through induction of immune-related genes (Li and Verma, 2002). In addition, NFκB activation upon HCMV infection facilitates viral immediate-early gene transcription and protein expression at late times of the HCMV replication cycle (Sambucetti et al., 1989; Yurochko et al., 1995). Recent evidence shows that NFκB activation is not required for HCMV replication in fibroblasts but NFκB signalling is important for the production and efficiency of antiviral factors such as TNF and IFN (Benedict et al., 2004; Eickhoff and Cotten, 2005). HCMV establishes latency in cells of the myeloid lineage and, although NFκB may be involved in virus neutralization, NFκB’s exact role in virus reactivation and pathogenesis in vivo is not fully understood (Jarvis and Nelson, 2002). HCMV prevents external signalling to the cell by reducing cell surface expression of the 55-kDa TNFRI, a receptor that activates several signal transduction pathways including NFκB (Bailie et al., 2003). At the same time, we show that HCMV triggers NFκB signalling by expression of UL144, allowing the virus to modulate this pathway for its own benefit.

The biological relevance of the cellular genes affected by UL144-induced NFκB activation for HCMV replication is of great interest. Here, we show that one end result of UL144-mediated NFκB activation is the expression of CCL22, a chemottractant for Th2 cells and regulatory T cells via CCR4 (Yoshie et al., 2001). Interestingly, this also parallels EBV since LMP1 triggers CCL22 expression (Nakayama et al., 2004). We propose that the upregulation of CCL22 will induce recruitment of Th2 cells that may unbalance an efficient antiviral Th1 response and, in addition, may enhance the migration of T regulatory cells with immunosuppressive properties to sites of infection. This would be complemented by the proposed additional function of UL144 as an inhibitor of T-cell activation through interaction with BTLA (Cheung et al., 2005) and by the ability of the chemokine receptor homologue US28 and the secreted chemokine binding protein UL21.5 encoded by HCMV to sequester CCL5, a chemokine that attracts Th1 cells and cytotoxic T cells via CCR5 (Bodaghi et al., 1998; Yoshie et al., 2001; Wang et al., 2004). These mechanisms would allow the virus to evade the host immune system. The results reported here establish a new function of UL144 that is demonstrated in the context of HCMV infection and consists of the subversion of the NFκB signalling pathway leading to upregulation of cytokines that may be advantageous for the virus.

Materials and methods

Cells and viruses

HFFs, U373 cells, Vero cells and 293 T cells were maintained in Eagle’s minimal essential medium containing 10% fetal calf serum. Infections with HCMV AD169, TB40E and Toledo have been described (Murphy et al., 2002; Baillie et al., 2003). The HCMV Towne used in these studies was CR(IE1-GFP), a recombinant that does not express UL144 and encodes a fusion of IE1 to GFP, a kind gift of R Greaves (Imperial College School of Medicine, London) (Murphy et al., 2002). Insect S9 and H15 cells were used for expression of recombinant proteins.

Plasmids

The reporter plasmid with the firefly luciferase gene under the control of the human IFN-β promoter, pIF-β125, the synthetic PRD multimer reporter p(PRDIII)3;tk(−39)lucifer and p(PRDIi)3;tk(−39)lucifer, the IFN-responsive ISRE reporter p(9–270)ISRE;tk−39lucifer and the NFκB-galactosidase reporter plasmid pATlac were provided by S Goodbourn (St George’s Hospital Medical School, University of London, UK) (Visvanathan and Goodbourn, 1989; Masson et al., 1992; King and Goodbourn, 1994, 1998; Poole et al., 2002). Plasmids containing wild-type CCL22 promoter (WT pGL3-CCL22, −722/−11) or with deletions pGL3−CCL22−ANFx82, pGL3−CCL22−ANFx82 and 2, pGL3-CCL22−AP1, pGL3-CCL22−ANFx82 and 2 and AP1) and the empty vector pGL3 are kind gifts of Dr O Yoshie (Kinki University School of Medicine, Osaka, Japan) (Nakayama et al., 2004). Expression of UL144 in mammalian cells was achieved by PCR of the UL144 gene from HCMV Toledo with primers 5’-CTAAGCCTGTAGGACCGGAT 3’ (HindIII) and 5’-ATTGCTAGCCAGGGTGCGGTA 3’ (NotI) (C-terminal tag) or 5’-CAGCGATCCAGTACTAAGAGCTGCT 3’ (BamHI) and 5’-ATGGGCCGCTCTAGAGCTGAGGTA 3’ (NotI) (N-terminal tag) and subcloning into pcDNA3 (Invitrogen) engineered to contain an N-terminal CD33 signal sequence followed by a T7 tag or a C-terminal T7 tag, provided by B Aguado (Centro de Biología Molecular, Madrid, Spain). Plasmids expressing UL144 with N- or C-terminal T7 tags were named pcDNA3UL144-T7N or pcDNA3UL144-T7C, respectively. Unless otherwise stated, both of these constructs were used in the experiments and the tag did not affect any of the UL144 functions tested. GFP65 was a kind gift from W Greene (Graduate Institute of Virology and Immunology, University of California, San Fransisco) and GFP-IFR3 from S Goodbourn. T7 tagged WT-1 plasmid, pcDNA3WT1, was a kind gift of Dr H Hastie (HGR, MRC, UK). The pBAC-1 plasmid (Novagen) expressing C-terminal his-tagged UL144 from HCMV Toledo in the baculovirus system was generated by PCR of the UL144 gene encoding the extracellular domain and lacking the transmembrane domain with primers: 5’-AGAGGAGTTCATGAGCTGCTGAGGTA 3’ (BamHI) and 5’-TCCGGGCGAGAAACACGAGGTCGAGCT3’ (NotI). The DNA sequence of the constructs was confirmed.

Gene expression and protein analysis

For reporter gene assays, plasmids were transfected with Lipofectamine 2000 using the standard protocol except that growing seedling overnight, cells were incubated for 5 h in OPTI MEM (Invitrogen), before transfection, allowing transfection of up to 80% of cells as assessed by immunofluorescence. Lysates were prepared and analysed for luciferase and β-galactosidase activity (King and Goodbourn, 1994). For immunoprecipitations, pcDNA3UL144-T7N or pcDNA3 transfected cells were lysed in EBC buffer (50 mM Tris/Cl pH 8.0, 200 mM NaCl, 200 μM NaF, 10 mM EDTA and 50 μM PMSF; supplemented with 40 μg/ml BSA) and cellular debris removed by centrifugation. Lysates were precleared by addition of control lgs and protein A-Sepharose beads. For UL144 immunoprecipitation, cell lysates were incubated with anti-T7 antibody (Novagen) or isotype matched control antibodies followed by protein A-Sepharose (1:1) and washed with NETN (20 mM Tris/Cl pH 8.0, 100 mM NaCl, 1 mM EDTA and 0.5% (v/v) NP40). Immunoprecipitates were resuspended in Laemmli’s...
buffer and proteins separated by SDS-PAGE. Proteins were then transferred to Hybond-C (Amersham Biosciences) and Western blotted with an anti-TRAF6 antibody (Abcam). Lysates from siRNA-transfected cells were Western blotted with anti-TRAF6 or anti-TRAF2 antibodies (Abcam). Rabbit polyclonal antibodies to NFκB p100 or GAPDH were from Cell Signalling or Abcam, respectively.

**Design and transfection of siRNA**

Removal of TRAF6 or UL144 by siRNA was achieved using three custom designed siRNA primers (Dharmacon) with the following sequences:

1. 5′-AACCAACAGCACAATCTAG-3′, 5′-AACGATCATGTAAC-3′, 5′-AACAGTTGTGGTACAA-3′ for TRAF6.
2. 5′-AAGATGGAAAAGGAGGAACCCGTTAATATG-3′, 5′-AACGGACAAAGGACAGCAATAT-3′ for TB40E.
3. 5′-AAGTTTCATGTCCTGTGCTG-3′, 5′-AAGAAGTGTTACTAACGTTATGCA-3′ and 5′-AATATTAGGGTACGTACCT-3′ for UL144 from HCMV TB40E.

The siRNA for NFκB p101, NFκB p100 and TRAF2 were purchased from Qiagen. HFF or U373 cells in six-well plates were transfected with Lipofectamine 2000 at 3.3 μl of each siRNA (Dharmacon) or 9.9 μl of control or Qiagen siRNA. Infections with 5 PFU per cell were performed 24 h post-transfection and supernatants collected 48 h postinfection for quantification of CCL22 by ELISA. Alternatively, cells were lysed at the indicated time after transfection for reporter assay analysis or harvested directly into Laemmli’s buffer. The levels of TRAF6 and TRAF2 were measured by Western blotting with anti-TRAF6 or anti-TRAF2 antibodies (Abcam), respectively. For Western blotting, proteins were detected by enhanced chemiluminescence using horseradish peroxidase conjugated sheep anti-mouse or donkey anti-rabbit IgG (Cell Signalling). UL144 levels in U373 cells after siRNA transfection were measured by RT-PCR. Total RNA was isolated using the RNAeasy isolation system (Qiagen). After removal of the residual genomic DNA with DNase (Promega), first-strand cDNA was produced using the Promega RT System. PCR was performed using kit primers for GAPDH and 5′-GGCACGTATGTATCGG-3′ and 5′-CCGCCTTTTCTTCTTCTT-3′ for Toledo UL144 and 5′-TCAGCTTTGTGCCCTACAA-3′ and 5′-CGGTCCGTGTGCTGATGTCTT-3′ for TB40E UL144 as predicted by ‘Primer 3’ (http://frodo.wi.mit.edu/cgi-bin/primer3).

**Immunofluorescence and FRET**

Cells were fixed and permeabilized (4% formaldehyde in PBS for 30 min RT, followed by 5 min RT of 25, 50, 75 and 100% ethanol consecutively). Cells were then rehydrated in decreasing concentrations of ethanol before washing in PBS. For GFP expressing cells, TO-PRO3 was added to the cells at a final concentration of 100 μg/ml or was transfected into cells using Lipofectamine 2000 (Invitrogen) under conditions specified by the manufacturer. Human recombinant TNF and type I human IFN-α2a (RND systems) was diluted in running buffer HBS-EP, pH 7.4/150 mM NaCl/3 mM EDTA/0.005% polysorbate 20 (vol/vol) and applied individually to the sensor chip (30 μl/min). The UL144 sensor chip was regenerated with 10 mM acetate, pH 2.0. The data were analysed using the Biaevaluation 3.0 software.

**Acknowledgements**

We thank Yin Ho, Begoña Ruiz-Angiulli and Ali Alejo for help with the SPR (BIAcore) analysis; Mark Bain, Mark Wills and Matthew Reeves for advice on siRNA experimental technique and RT–PCR; Mark wills, Georgina Brown and Joan Baillie for virus stocks; and Steve Goodbourn for his luciferase reporter assay method. This work was funded by the Wellcome Trust.

**References**


Masson N, Ellis M, Goodbourn S, Lee KA (1992) Cyclic AMP response element-binding protein and the catalytic subunit of protein kinase A are present in F9 embryonal carcinoma cells but are unable to activate the somatostatin promoter. Mol Cell Biol 12: 1096–1106


Sambucetti LC, Cherrington JM, Wilkinson GW, Mocarski ES (1989) NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. EMBO J 8: 4251–4258


© 2006 European Molecular Biology Organization